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http://www.molecular-cancer.com/content/13/1/132RESEARCH Open AccessUSP18 is crucial for IFN-γ-mediated inhibition of
B16 melanoma tumorigenesis and antitumor
immunity
Bangxing Hong, Haiyan Li, Yong Lu, Mingjun Zhang, Yuhuan Zheng, Jianfei Qian and Qing Yi*Abstract
Background: Interferon (IFN)-γ-mediated immune response plays an important role in tumor immunosurveillance.
However, the regulation of IFN-γ-mediated tumorigenesis and immune response remains elusive. USP18, an interferon
stimulating response element, regulates IFN-α-mediated signaling in anti-viral immune response, but its role in
IFN-γ-mediated tumorigenesis and anti-tumor immune response is unknown.
Method: In this study, USP18 in tumorigenesis and anti-tumor immune response was comprehensively appraised in vivo
by overexpression or downregulation its expression in murine B16 melanoma tumor model in immunocompetent and
immunodeficient mice.
Results: Ectopic expression or downregulation of USP18 in B16 melanoma tumor cells inhibited or promoted
tumorigenesis, respectively, in immunocompetent mice. USP18 expression in B16 melanoma tumor cells regulated
IFN-γ-mediated immunoediting, including upregulating MHC class-I expression, reducing tumor cell-mediated inhibition
of T cell proliferation and activation, and suppressing PD-1 expression in CD4+ and CD8+ T cells in tumor-bearing mice.
USP18 expression in B16 melanoma tumor cells also enhanced CTL activity during adoptive immunotherapy
by prolonging the persistence and enhancing the activity of adoptively transferred CTLs and by reducing CTL exhaustion
in the tumor microenvironment. Mechanistic studies demonstrated that USP18 suppressed tumor cell-mediated immune
inhibition by activating T cells, inhibiting T-cell exhaustion, and reducing dendritic cell tolerance, thus sensitizing tumor
cells to immunosurveillance and immunotherapy.
Conclusion: These findings suggest that stimulating USP18 is a feasible approach to induce B16 melanoma specific
immune response.
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The immune system has developed specific mechanisms to
induce tumor immunosurveillance and antitumor immune
responses [1-3]. These include activation of innate immune
cells, such as NK cells and phagocytes, and the tumor
antigen-specific adaptive immune response. Cytotoxic T
lymphocytes (CTLs) are the main adaptive immune cells
which lyse tumor cells in an antigen-specific manner [4].
Activated NK cells and CTLs secrete various effector
molecules to lyse tumor cells. They both secrete the
type-II interferon, IFN-γ, to enhance anti-tumor activity,* Correspondence: yiq@ccf.org
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unless otherwise stated.which includes enhancing antigen presentation and pro-
moting the proliferation, expansion and survival of CD8+ T
cells [5,6]. IFN-γ is a pleiotropic cytokine that has diverse
biological functions [7] and binds to cognate receptors at
the cell surface and activates the JAK-STAT pathway to in-
duce expression of IFN -stimulated genes (ISGs) [8]. Sev-
eral mechanisms exist to terminate IFN-γ signaling,
including induction of SOCS family protein expression
[9,10]. In contrast, the type-I IFN-α/-β can induce
ubiquitin-specific protease 18 (USP18) expression to at-
tenuate type-I IFN signaling [11,12]. USP18 regulates type-I
IFN signaling through its deubiquitinase activity towards
free ISG15 production, but also binds the IFNAR2 receptortd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Hong et al. Molecular Cancer 2014, 13:132 Page 2 of 12
http://www.molecular-cancer.com/content/13/1/132to inhibit JAK/STAT activation [12]. Whether USP18 also
regulates IFN-γ signaling is still not completely understood.
In this report, we investigated the function of USP18
in IFN-γ signaling in B16 melanoma cells in vitro and
in vivo and found that IFN-γ or CTLs activated USP18
expression in tumor cells. Mechanistic studies using
immuocompromised mice or immune cells depletion, or
antigen-specific CTL immunotherapy showed that USP18
expression in B16 melanoma cells was essential for main-
taining tumor antigen-specific CTL activity, persistence,
and for IFN-γ signaling-mediated tumor immunesurveil-
lance. This study is not only important for elucidating the
regulation of CTL immunotherapy, but also provides a sci-
entific basis for developing novel immunotherapeutic strat-
egies to target USP18 in B16 melanoma cells to induce
innate and adaptive immune responses against tumors.
Materials and methods
Materials and antibodies
Adenovirus containing mouse USP18 (Ad-mUSP18)
was purchased from Applied Biological Materials Inc.
(Richmond, BC, Canada). We prepared lentivirus con-
structs containing mouse USP18 shRNA. Rabbit and goat
anti-mouse USP18 antibodies were kindly provided by Dr.
Ethan Dmitrovsky (Dartmouth-Hitchcock Medical center,
Dartmouth College, USA) or purchased from Santa Cruz
Biotechnology.
Mouse models
C57BL/6, NOD-SCID-IL2Rγ−/− (NSG), Ifng−/−, OT-1 and
OT-2 C57BL/6 and pmel-1 C57BL/6 transgenic mice were
purchased from Jackson Laboratory. All mice were 6- to
7 weeks of age at the time of experiment, and at least 5
mice per group were used in each experiment. Mice were
housed and experimental procedures were performed in ac-
cordance with the IACUC guidelines at University of Texas
MD Anderson Cancer Center and Cleveland Clinic.
Generation of stable USP18 overexpression and
knockdown cancer cells
Overexpression of USP18 into the tumor cell line B16 was
accomplished by transduction of adenovirus Ad-mUSP18
followed by cell sorting to select GFP-positive tumor cells
(B16-USP18, B16-OVA-USP18). Stable knockdown of
USP18 was accomplished by lentivirus shUSP18 transduc-
tion of B16 and B16-OVA tumor cells and sorting for GFP-
positive tumor cells (B16-shUSP18, B16-OVA-shUSP18).
Subcutaneous and intravenous B16 melanoma models
Subcutaneous and intravenous murine melanoma models
were established as described elsewhere [13]. Briefly, for the
subcutaneous tumor model, 0.5- to 1.0 million B16-OVA-
shCon, B16-OVA-USP18, B16-OVA-shUSP18 tumor cells
were subcutaneously inoculated. For the intravenous tumormodel, 0.3- to 1.0 million of tumor cells were intravenously
injected, and lung tumor foci were counted to assess tumor
burdens. In some experiments, the tumor model was first
established, followed by adoptive transfer of antigen-
specific CTLs to the tumor-bearing mice.
Flow cytometry and cell sorting
Cells from tumor, spleen, lymph nodes and lung were
mechanically dissociated, and the red blood cells were
removed by ACK lysis buffer (Lonza). Cells were first
blocked with Fc antibody and then labeled with different
combinations of antibodies. Data were acquired with
an LSR Fortessa flow cytometer (BD Biosciences), and
analysis was performed using Flowjo software. Cell sor-
ting was performed using a BD FACSAria cell sorter
(BD Biosciences). Fluorochrome conjugated CD4, CD8,
CD11b, NK1.1, PD1, NKG2D, CD86, MHC I, MHC II,
KLRG1, IFNγ and TNFα were bought from BD Biosciences.
PE conjugated OT-1 tetramer were bought from Beckman
Coulter, Inc.
Cell proliferation and apoptosis assays
Cell proliferation was assessed by a BrdU incorporation
assay. Cells cultured in vitro were treated with 10 μM
BrdU for 30 min or 16 hrs when the cells were in expo-
nential growth. Cells were harvested and stained with
BrdU-APC/7AAD. For apoptosis assay, cells were cul-
tured until they reached exponential growth and then
were collected and stained with Annexin-V/PI.
Western blot
Cell lysates, 20 μg, were electrophoresed on 4-12% SDS-
PAGE gels, and transferred onto 0.22 μm nitrocellulose
membrane (Hybond, Amersham Biosciences, Inc.). The
membrane was then incubated with specific antibody
followed by horseradish peroxidase-conjugated secondary
antibody (Amersham Biosciences, Inc.). The expressed
protein was detected with an ECL Plus Western blotting
detection kit (Amersham Biosciences, Inc.).
qRTPCR
mRNA was prepared from cells or tissues using a Qiagen
RNAeasy Kit. cDNA was synthesized using an ABI Biosys-
tems cDNA synthesis kit. Quantitative PCR was conducted
with SYBR Green Master Mix (Life Technologies) and run
in an ABI750 thermal cycler. The primers for USP18 are:
5′-atgcaggacagtcgacagaa-3′ and 5′- tgtcaagtctgtgtccgtga-3′.
Immunohistochemisty staining
Paraffin-embedded tumor tissues were processed with
pH9.0 antigen retrieval buffer. The slides were blocked
with 3% H2O2 and the serum of the species of secondary
antibody. The primary antibody was incubated at 4°C
overnight. Slides were washed and secondary antibody
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were washed three times with 1 × PBST and then devel-
oped with DAB and counterstained with H&E and
mounted for microcopy analysis.
Coculture of OT-1 and OT-2 cells with B16-OVA-USP18
tumor cells
B16-OVA-GFP or B16-OVA-USP18 tumor cells were
cocultured with or without IFN-γ sensitization (5 ng/ml)
and subjected to low dose (10 Gy) irradiation. OT-1-
and OT-2-naive T cells were cocultured with irradiated
tumor cells for 48- to 72 hours. T-cell proliferation was
analyzed by a CFSE dilution assay or 3H-incorporation
assay. IL-2 and IFN-γ secretion from cocultured T cells
was analyzed by ELISA.
Statistical analysis
Groups were compared using a student’s t-test. Differ-
ences were considered significant when p < 0.05. All data
are presented as mean ± SEM.
Results
IFN-γ signaling induces USP18 expression in tumor cells
during immunosurveillance
IFN signaling plays important roles in cell activity, in-
cluding cell growth, differentiation, proliferation, and
immune regulation. IFN signaling also is critical for
immunosurveillance for tumorigenesis and metastasis
[5], including surveillance for induction of MHC class-I
molecule expression on tumor cells [14]. We first veri-
fied that IFN-α/-β or IFN-γ stimulation increased MHC
class-I expression on tumor cells (Additional file 1:
Figure S1A). Inoculated tumor cells in IFN-γ signaling-
deficient (Ifng−/−) mice had reduced MHC class-I expres-
sion (Additional file 1: Figure S1B).
IFN signaling is regulated by various molecules and the
canonical factors are the IFN-sensitive response elements
(ISREs) [8]. USP18 is an IFN stimulated gene that has been
reported to regulate type-I IFN signaling in the anti-viral
immune response [12]. To our knowledge, very few studies
have investigated USP18 regulation of type-II IFN signaling
in tumor immunosurveillance. We assessed USP18 mRNA
and protein levels in B16 tumor cells after IFN-α or IFN-γ
stimulation and found that IFN-γ was a more potent in-
ducer than IFN-α for USP18 expression (Figure 1A and
B), as well as Stat1 phosphorylation, which is IFN-γ signal-
ing downstream gene (Figure 1B). Western blot analysis
showed that IFN-γ induced USP18 protein expression in
other tumor cell lines such as 4 T1 and EMT6 tumor cells
(Figure 1C). To investigate whether endogenous IFN signal-
ing induces USP18 expression during tumor development
in vivo, we inoculated C57BL/6 mice with B16-GFP tumor
cells. Tumor cell USP18 expression was increased in vivo
as compared with in vitro conditions (Figure 1D). Toexamine exogenous IFN signaling, such as CTL secretion
of IFN-γ, we performed adoptive transfer of activated OT-1
cells, which resulted in stronger USP18 expression in tumor
cells in vivo (Figure 1D). Similar results were found in in vi-
tro coculture (Figure 1E). These results demonstrated that
USP18 was expressed in tumor cells during tumor develop-
ment regardless of whether IFN signaling was endogenous
or exogenous.
USP18 expression in tumor cells suppresses tumor
growth in vivo
To determine whether tumor cell USP18 expression con-
tributes to tumorigenesis in vivo, we stably silenced or
ectopically expressed USP18 in B16-OVA tumor cells
(Additional file 1: Figure S2A and B). As IFN signaling
was required for USP18 expression in tumor cells, knock-
down of USP18 was confirmed after IFN-γ stimulation
(Additional file 1: Figure S2A). We found that USP18
knockdown or overexpression did not affect the prolifera-
tion or apoptosis status of the cells, either with or without
IFN-γ stimulation (Additional file 1: Figure S2C and D).
B16-OVA-shCon (control), B16-OVA-shUSP18 (USP18
knockdown), or B16-OVA-USP18 (USP18 overexpression)
cells were then intravenously inoculated into immunocom-
petent C57BL/6 mice. Knockdown of USP18 expression
significantly increased tumor burden in C57BL/6 mice
(Figure 2A and B, and Additional file 1: Figure S3) and
shortened mouse survival time (Figure 2C). Conversely,
overexpression of USP18 in B16-OVA tumor cells signifi-
cantly reduced tumor burden in C57BL/6 mice (Figure 2D
and E, and Additional file 1: Figure S3) and prolonged
mouse survival time (Figure 2F). As tumor cells were intra-
venously injected into mice, the change in tumor burden
was not due to the difference of invasion or migration of
tumor cells (Additional file 1: Figure S4A-C).
In order to confirm this finding, we subcutaneously in-
oculated B16-OVA-shCon, B16-OVA-shUSP18, or B16-
OVA-USP18 tumor cells into C57BL/6 mice. Tumor
growth in mice receiving B16-OVA-USP18 cells was sig-
nificantly inhibited, whereas tumor growth was en-
hanced in those receiving B16-OVA-shUSP18 tumor
cells (Figure 2G-I).
USP18 function in tumor growth depends on the
immune system
To explore whether regulation of tumorigenesis by USP18
expression in tumor cells was due to host immune status,
we intravenously inoculated B16-OVA-GFP or B16-OVA-
USP18 tumor cells into NSG (NOD-SCID/IL2Rγ−/−) mice,
which are deficient in T, B and NK cells. In contrast to im-
munocompetent mice, ectopic expression of USP18 did not
inhibit tumorigenesis in NSG mice (Figure 3A and B), and
no significant difference of survival in tumor-bearing mice
was noted (Figure 3C). However, the tumor burden was
Figure 1 USP18 expression in tumor cells with IFN-γ signaling. B16 tumor cells were stimulated in vitro with IFN-γ (10 ng/ml) (R&D systems),
IFN-α (10 ng/ml) (R&D systems), or LPS (1 μg/ml) (Invivogen) for 24 hr, then harvested for qRT-PCR assay of USP18 mRNA (A) and Western blot
assay (B) of USP18 and pStat1 protein expression. EMT6 and 4 T1 tumor cells were untreated or treated with IFN-γ (5 ng/ml) for 24 hr, USP18
expression was analyzed by Western blot analysis (C). B16-GFP cells were subcutaneously inoculated into C57BL/6 mice until tumor sizes reached
about 5 mm. Some mice received adoptive transfer of 5 × 106 activated OT-1 cells for 48 hr. B16-GFP tumor cells were collected and qRT-PCR
analysis of USP18 expression (D). B16 tumor cells were cocultured with activated OT-1 cells for 24 hr and analyzed for USP18 and pStat1
expression (E).
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mice for both the B16-OVA-USP18 and B16-OVA-GFP in-
oculation groups, suggesting that lack of the immune sys-
tem or immunosurveillance enabled the tumor cells to be
more aggressive [15].
CD4+ and CD8+ T cells and NK cells are the principal
IFN-γ-producing cells, and their anti-tumor activity de-
pends on the robustness of IFN-γ production. To deter-
mine how tumor cell USP18 affects these cells and thus the
immune response, we injected B16-OVA-GFP or B16-
OVA-USP18 tumor cells into C57BL/6 mice that were de-
pleted of CD4+ or CD8+ T cells or NK cells and monitored
tumorigenesis. CD8+ T cell depletion significantly compro-
mised the effect of USP18 expression on tumorigenesis
(Figure 3D-E). However, CD4+ T cell or NK cell depletion
was less important in USP18-mediated tumorigenesis
(Figure 3D-E). To further investigate the function of
USP18 in IFN-γ-mediated immune surveillance against
tumorigenesis, B16-OVA-GFP and B16-OVA-USP18 cells
were intravenously injected into IFN-γ-knockout or wide-
type C57BL/6 mice. Tumor nodule formation was similar
when B16-OVA-GFP and B16-OVA-USP18 cells were in-
oculated (intravenously) into IFN-γ-knockout (KO) mice
(Figure 3F-G). These results showed that regulation of tu-
morigenesis by USP18 depended on IFN-γ signaling, most
likely through the IFN-γ-mediated immune response.USP18 expression in tumor modulates immune cell
population and phenotype
During tumor development, a variety of mechanisms in-
hibits the host immune response, including secretion of in-
hibitory cytokines and chemokines [16] and cell-cell
contact suppression [17]. To explore USP18 function in im-
mune suppression, we analyzed the immune status in the
tumor microenvironment after USP18 overexpression in
tumor cells (B16-OVA-USP18), which were then intraven-
ously injected in C57BL/6 mice. CD45+ cell infiltration of
the lung increased (Figure 4A). The percentage and the ab-
solute number of NK cells also increased, but CD11b+ mye-
loid cell infiltration decreased (Figure 4A). Monitoring of
SIINFEKL MHC class-I-restricted tetramer-positive CD8+
cells in the lung, spleen and draining lymph nodes revealed
an increased antigen-specific CTL response in B16-OVA-
USP18 tumor-bearing mice (Figure 4B).
Host immunosurveillance against tumorigenesis is not
only determined by the potency of the antigen-specific
immune response, but also by the persistence of immune
effector cells [18]. Tumor cells have developed specific
mechanisms to induce tolerance, inhibition, and exhaus-
tion of immune effector cells, by altering the expression
of PD-1 and KLRG1 on T cells [19,20]. Analysis of PD-1
expression in CD8+ T cells from B16-OVA-USP18
tumor-bearing mice showed a reduced PD-1 expression
Figure 2 USP18 expression in tumor cells suppresses tumor growth in vivo. 3 × 105 B16-OVA-shUSP18 or B16-OVA-shCon tumor cells
were intravenously inoculated into C57BL/6 mice. Tumor growth was monitored by counting the lung tumor foci (A-B) and the survival rate
(C). 2 × 105 B16-OVA-USP18 or B16-OVA-GFP tumor cells were intravenously inoculated into C57BL/6 mice. Tumor growth was monitored by
counting the lung tumor foci (D-E), and mouse survival rate over time (F). 1 × 106 B16-OVA-USP18 or B16-OVA-GFP, or B16-OVA-shUSP18 tumor
cells were subcutaneously inoculated into C57BL/6 mice. The tumor growth was monitored as tumor volume and by H&E staining (G-I).
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B16-OVA-GFP tumor-bearing mice (Figure 4C).
We speculated that USP18 expression in tumor cells
might lead to secretion of soluble factors that also con-
tribute to the immune activation. Cytokine array analysis
of culture supernatant from USP18 overexpression and
knockdown B16-OVA tumor cells did not show signi-
ficant differences (Additional file 1: Figure S5A), but
analysis of a chemokine panel showed that in B16-OVA-
USP18 cells, increased secretion of chemokines related
to NK cell migration was observed (Additional file 1:
Figure S5B). In regard to NK cells, not only did the ratio
and absolute number of infiltrating NK cells increased in
B16-OVA-USP18 tumor-bearing mice (Figure 4A), but
the activation status of the infiltrating NK cells also in-
creased, as evidenced by detection of the activation re-
ceptor NKG2D (Figure 4D).
ISG15 is an IFN-induced gene that is regulated by
USP18 [21]. In free form, ISG15 can activate NK cells
and antigen presentation cells [22,23], and a recent study
showed that human ISG15 deficiency leads to myco-
bacterial disease [24]. To detect ISG15 in the tumor
microenvironment, tumor lysate was prepared from B16-OVA-GFP, B16-OVA-USP18 or B16-OVA-shUSP18 tu-
mors, and ELISA or western blot analysis showed that
the ISG15 level was higher in B16-OVA-USP18 tumor
than in B16-OVA-GFP tumor, but lower in B16-OVA-
shUSP18 tumor (Figure 4E, Additional file 1: Figure S6).
We further investigated dendritic cell activity in the
tumor microenvironment. CD11c+ dendritic cells were
tolerized in the tumor stroma during tumor develop-
ment [25]. Isolation of CD11c+ dendritic cells from B16-
OVA-USP18 tumor bearing mice showed that these cells
were activated instead of tolerized, because the expres-
sion of CD86 and MHC class-II was higher (Figure 4F),
and more TNF-α but less IL-10 were secreted after re-
stimulation in vitro as compared with B16-OVA-GFP
tumor bearing mice (Figure 4G).
USP18 expression inhibits immune suppression mediated
by tumor cells
As USP18 expression in tumor cells affects CD8+ T-cell
function in vivo, B16-OVA-GFP or B16-OVA-USP18
cells were irradiated and then cocultured with OT-1 T
cells in vitro to analyze T-cell activation. B16-OVA-
USP18 tumor-cell coculture significantly increased OT-
Figure 3 USP18 function in tumor growth depends on the immune system. 3 × 105 B16-OVA-USP18 or B16-OVA-GFP tumor cells were
intravenously inoculated into NSG mouse. The tumor burden (A-B) and mice survival rate (C) were analyzed. 3 × 105 B16-OVA-USP18 or
B16-OVA-GFP tumor cells were intravenously inoculated into C57BL/6 mice with or without depletion of CD8+ or CD4+ T cells, or NK1.1+ NK cells,
and the tumor burden in the lung was monitored (D-E). 3 × 105 B16-OVA-GFP, or B16-OVA-USP18 tumor cells were intravenously inoculated into
C57BL/6, or Ifng−/− B6 mice. Tumor growth was monitored (F-G).
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OT-1 T-cell secretion of IL-2 and IFN-γ (Figure 5B).
Moreover, secretion of IL-2 and IFN-γ was even grea-
ter when OT-1 T cells were cocultured with IFN-γ-
sensitized B16-OVA-USP18 tumor cells as compared
with B16-OVA-GFP cells (Figure 5C). Activated T cells
express inhibitory molecules, such as PD-1, to prevent
over-activation [26]. We found that ectopic expression
of USP18 in B16-OVA cells significantly inhibited PD-1
expression on cocultured OT-1 T cells (Figure 5D). This
phenomenon was also seen in T cells from B16-OVA-
USP18 cell inoculated mice (Figure 4C). Moreover, ectopic
USP18 expression in B16-OVA tumor cells significantly
increased the CTL activity of activated OT-1 cells in vitro
(Figure 5E). CD4+ T cells also played a role in tumor
immunosurveillance. Irradiated B16-OVA-USP18 cells
stimulated OT-2 T cells to proliferate (Figure 5F) and se-
crete more IL-2 and IFN-γ (Figure 5G) after the coculture.
Furthermore, overexpression or knockdown USP18 in
B16-OVA cells did not affect OVA antigen expression
level in tumor cells (Additional file 1: Figure S7),excluding the possibility that USP18 could regulate
antigen expression.
Inhibition USP18 activity in tumor cells compromises
antigen-specific CTL activity
As we found that endogenous IFN-γ signaling affected
tumorigenesis through IFN-γ-induced USP18 expression
in tumor cells and regulated immune-cell function in
the tumor microenvironment, we wanted to explore
whether USP18 expression in tumor cells affected ex-
ogenous IFN-γ-secreting CTL activity. Antigen-specific
IFN-γ-secreting CTLs play an important role in antitumor
immunity [27]. To analyze CTL activity in B16-OVA-
shCon and B16-OVA-shUSP18 tumors, we intravenously
injected 1 × 106 B16-OVA-shCon cells or B16-OVA-
shUSP18 cells into CD45.1+ C57BL/6 mice for 8 days,
followed by adoptive transfer of 5 × 106 activated OT-1
(CD45.2+) cells into tumor-bearing mice. Monitoring for
persistence of CD45.2+ OT-1 cells in the lung, draining
lymph nodes and spleen of tumor-bearing mice showed
that OT-1 CTLs were rapidly exhausted in B16-OVA-
Figure 4 USP18 expression in tumor modulates immune cell population and phenotype. C57/BL6 mice received intravenous inoculation of
3 × 105 B16-OVA-USP18 or B16-OVA-GFP tumor cells. 2 weeks later, T cell, CD11b+ myeloid cell and NK cell infiltration in the lung was analyzed by
flow cytometry (A). Antigen-specific OT-1 tetramer-positive CD8+ T cells in the lung draining lymph nodes (DLN), lung, and spleen were analyzed
(B). PD-1 expression on CD8+ T cells (C) was analyzed. NKG2D expression on NK cells in tumor microenvironment was monitored by flow
cytometry (D). ISG15 levels in B16-OVA-GFP, B16-OVA-USP18 or B16-OVA-shUSP18 tumor lysate was analyzed by ELISA (E). CD11c+ dendritic cells
were isolated from B16-OVA-GFP, or B16-OVA-USP18, and B16-OVA-shUSP18 lung melanoma and cultured in vitro with or without LPS. Dendritic
cell maturation and cytokine were assayed by flow cytometry and ELISA, respectively (F-G).
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(Figure 6B) and intracellular staining for IFN-γ and TNF-
α (Figure 6C) demonstrated a loss of CTL activity in B16-
OVA-shUSP18 tumor-bearing mice. Analysis of the T-cell
exhaustion markers PD-1 and KLRG1 showed that the ex-
pression of these molecules was greater on OT-1 cells in
B16-OVA-shUSP18 tumor-bearing mice than B16-OVA-
shCon tumor-bearing mice (Figure 6D). These data indi-
cated that USP18 expression in tumor cells regulated the
IFN-γ-secreting activity and persistence of the CTLs in
the tumor microenvironment.
Ad-USP18 and CTL combination immunotherapy in
subcutaneous B16 melanoma model
Our study showed that USP18 expression in tumor cells
regulated tumorigenesis and IFN-γ secretion by exogen-
ous CTLs as part of the anti-tumor immune response.Next, we investigated the possibility that use of USP18
could enhance CTL activity against subcutaneous B16
melanoma. After B16-OVA-GFP, B16-OVA-USP18, or
B16-OVA-shUSP18 tumor cells were subcutaneously in-
oculated into C57BL/6 mice, tumor growth in mice re-
ceiving B16-OVA-USP18 cells was significantly inhibited,
whereas tumor growth was promoted in those receiving
B16-OVA-shUSP18 tumor cells (Figure 2G). Next, we de-
termined whether MHC class-I and PD-L1 expression dif-
fered in subcutaneous B16-OVA-USP18 tumor from that
of B6-OVA-GFP tumor. Results showed that ectopic ex-
pression of USP18 increased MHC class-I and reduced
PD-L1 expression (Figure 7A). As MHC class-I and PD-L1
expression on tumor cells significantly affected host immu-
nosurveillance, we also detected greater OT-1 tetramer-
positive CD8+ CTL infiltration in B16-OVA-USP18 tumor
than those in B16-OVA-GFP tumor (Figure 7B). Moreover,
Figure 5 Immune suppression by tumor cells is regulated by USP18 expression. B16-OVA-GFP or B16-OVA-USP18 tumor cells without (A-B)
or with IFN-γ sensitization (5 ng/ml) (C) were irradiated and cocultured with naïve OT-1 T cells. Cell proliferation (A) and IL-2 and IFN-γ secreteion (B-C)
of the T cells were analyzed. PD-1 expression in cocultured OT-1 cells was monitored by flow cytometry (D). The CTL activity of activated OT-1 cells
against B16-OVA-GFP and B16-OVA-USP18 was analyzed (E). B16-OVA-USP18 cells with or without IFN-γ (10 ng/ml) sensitization were irradiated and
cocultured with naive OT-2 T cells for 72 hrs, and OT-2 T-cell proliferation (F) and cytokines IL-2 and IFN-γ secreteion (G) were analyzed.
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tumor and spleen compared with B16-OVA-GFP tumor
and spleen (Additional file 1: Figure S6A and B). However,
there was no difference in infiltrating regulatory T cells be-
tween B16-OVA-USP18 and B16-OVA-GFP subcutaneous
tumor (Additional file 1: Figure S6C).
Next we explored whether delivery of USP18 into the
tumor microenvironment enhances CTL activity against
subcutaneous B16-OVA tumor. A subcutaneous B16-OVA
tumor model was established in C57BL/6 mice. At day 5, ac-
tivated OT-1 CTLs were adoptively transferred to the mice,
together with intra-tumor injection of adenovirus vector ex-
pressing USP18 (Ad-USP18). Adoptive transfer of OT-1
CTLs induced partial tumor shrinkage (Figure 7C). Ad-
USP18 injection increased OT-1 CTL activity and tumor
shrinkage (Figure 7C). Detailed analysis of the immune sta-
tus in tumor-bearing mice showed that Ad-USP18 signifi-
cantly increased the duration of CTL persistence in the
spleen and tumor sites of tumor-bearing mice (Figure 7D).
As tumor antigens are weakly immunogenic, dendritic
cell vaccination and IL-2 treatment are usually used to
increase CTL activity clinically [28]. Using our B16
tumor model, we co-administered pmel-1 CTLs, Ad-USP18, IL-2 and dendritic cells into tumor. Injection of
Ad-USP18 significantly increased pmel-1 CTL activity
and caused tumor shrinkage (Figure 7E).
Discussion
The novel finding in this study is the discovery that the
ubiquitin-specific peptidase USP18 can be induced by IFN-
γ in tumor cells and plays important roles in inhibiting
tumorigenesis and antitumor immunity. We found that
USP18 is expressed in tumor cells after IFN-γ signaling
stimulation. Ectopic expression of USP18 in tumor cells
suppressed tumorigenesis and antitumor immune response
whereas inhibition of USP18 expression promoted tumori-
genesis and immunosurveillance. Mechanistically, USP18
expression in tumor cells modulated immune-cell popula-
tion and phenotype in tumor microenvironment. Moreover,
USP18 controlled exogenous IFN-γ producing antigen-
specific CTL persistence in antitumor immunity.
Many signaling pathways are involved in the regulation of
tumorigenesis and immunosurveillance. Type-I and-II IFNs
are central in a broad signaling network that regulates
tumor-cell proliferation and apoptosis, and modifies both
the anti-viral and antitumor immune responses. Type-I IFN
Figure 6 Inhibition of USP18 activity in tumor cells compromises antigen-specific CTL activity. CD45.1+ C57BL/6 mice received intravenous
inoculation of 1 × 106 B16-OVA-shCon and B16-OVA-shUSP18 tumor cells. At day 8, 5 × 106 activated CD45.2+ OT-1 CTLs were intravenously
injected into tumor-bearing mice. On day 10, the mice were sacrificed; CD45.2+ CTLs in lung, lung draining lymph nodes, and spleen were
analyzed for OT-1 tetramer expression on CD8+ T cells (gating on CD8+ cell population) (A-B), and IFN-γ and TNF-α (C), and PD-1 and KLRG1 (D).
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metastasis, e.g., genes suppressed in bone metastasis are tar-
gets of IFN regulatory factor 7 (IRF7) [29]. USP18 expres-
sion in tumor cells, such as human sarcoma 2fTGH cells, is
not only induced by IFNγ timulation [30]. Its expression or
mutation has also been reported to be disregulated during
tumorigenesis or treatment [31,32]. Combination with other
markers, USP18 can be used to predict the cancer patients
survival [33]. We found that USP18, which is induced by
IFN-α/-β in response to viral infection, is also expressed
in tumor cells after endogenous and exogenous type-II
IFN-γ signaling activation.
The mechanism underlying USP18 function in tumori-
genesis and antitumor immunity involves activation of
tumor immunosurveillance and alteration of the tumormicroenvironment. That endogenous IFN signaling through
USP18 controls tumorigenesis is evidenced by tumor
growth in the Ifng−/− mice after inoculation with B16-OVA-
USP18 or B16-OVA-shUSP18 tumor cells. However, it
should be noted that in this study, USP18 expression in
tumor cells not only affected tumor cell activity, but also
regulated immune cells in tumor microenvironment in that
tumor cell USP18 expression also activated CD11c+ den-
dritic cells residing in the tumor. Besides our report, USP18
has been reported to directly maintain oncogene stability
such as the chimeric, dominant-negative-acting transcrip-
tion factor promyelocytic leukemia gene (PML)/RARa dur-
ing acute promyelocytic leukemia development [34]. USP18
also stabilize cyclin D of tumor cells to inhibit apoptosis
[35]. All these reports suggested that USP18 may have both
Figure 7 Combination of Ad-USP18 and antigen-specific CTLs in subcutaneous B16 melanoma therapy. 1 × 106 B16-OVA-GFP or
B16-OVA-USP18 cells were subcutaneously inoculated into C57BL/6 mice (n = 5). Tumor MHC class-I and PD-L1 expression was analyzed by flow
cytometry (A). Antigen-specific CTLs in the spleen and tumor were analyzed as OT-1 tetramer-positive CD8+ T cells (B). 1 × 106 B16-OVA cells were
subcutaneously inoculated into CD45.1+ C57BL/6 mice. At day 5, tumor-bearing mice were treated with 5 × 106 activated CD45.2+ OT-1 cells
(intravenous) and intra-tumor injection of Ad-GFP or Ad-USP18 (1010 pfu in 50 μl). B16-OVA tumor growth was monitored. (C). Effector CD45.2+
CD8+ T-cell persistence was measured 15 days after tumor inoculation (D). 1 × 106 B16 cells were subcutaneously inoculated into C57BL/6 mice.
The tumor-bearing mice were treated with 5 × 106 activated pmel-1+ CTLs (intravenous) along with intra-tumor injection of Ad-GFP or Ad-USP18
(1010 pfu in 50 μl) with or without dendritic cell vaccination. B16 tumor growth was monitored after CTL and Ad-USP18 treatment (E).
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cells in the tumor environment.
Immunotherapy has become an important approach to
increase the efficacy of chemotherapy or radiotherapy [36].
Clinical trials have shown that after immunotherapy, some
melanoma and prostate cancer regressed [37]. Immuno-
therapy effectiveness is compromised because negative
regulation mechanism in the immune system [10,38]. Our
study showed that USP18 expression in tumor cells signifi-
cantly suppressed the expression of molecules responsible
for inhibiting CTL activity during immunotherapy. More-
over enhancing USP18 expression in primary tumors by
administration of adenovirus vector encoding USP18 sig-
nificantly increased antigen-specific CTL activity.
Gene therapy against tumor utilizes the delivery of
DNA into cells, which can be accomplished by a varietyof methods. Adenovirus vector is the efficient system to
deliver target DNA therapy in vivo [39], as it has higher
infection efficiency on both tumor cells and immune
cells. In our study, delivering USP18 into solid tumor
could be accomplished by intra-tumor injection of
adenovirus containing USP18 cDNA. Tumor micro-
environment contains a variety of other cells, such as
immune cells and stromal cells, and USP18 could regu-
late immune cells [12]. Manipulation of USP18 expres-
sion not only induces possible anti-apoptotic activity in
some cancers [35], but also change the tumor cell sensi-
tivity to immunotherapy. Moreover, overexpression of
USP18 in tumor cells may induce the immunesuppression
activity of MDSC in tumor environment. Further studies
will be performed to investigate the influence of Ad-USP18
on immune cells in tumor microenvironment.
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http://www.molecular-cancer.com/content/13/1/132In conclusion, we found that IFN-γ signaling induces
intrinsic expression of USP18 in tumor cells that not
only affects tumorigenesis, but also may be useful in
regulating immunotherapy efficacy.
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